5.1.3.14	biotechnology	production of erythropoietin (EPO) in Chinese Hamster Ovary (CHO) cells	
5.1.3.14	drug development	the enzyme is a target for development of antibiotic agent for treatment of infections caused by Gram-positive bacteria, such as Staphylococcus aureus and Bacillus anthracis	
5.1.3.14	drug development	Staphylococcus aureus is a leading cause of hospital and community-acquired infections by Gram-positive bacteria and Staphylococcus epidermidis has emerged as the most common cause of biofilm infections on medical implant devices. Enzyme MnaA serves as a Staphylococcal antibiotic target with cognate inhibitors predicted to possess dual therapeutic benefit: as combination agents to restore beta-lactam efficacy against MRSA and MRSE and as non-bioactive prophylactic agents to prevent Staphylococcal biofilm formation	
5.1.3.14	medicine	UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase interacts with the non-muscle form of alpha-actinin, alpha-actinin-1, in mature skeletal muscle cells. No significant difference in the binding of alpha-actinin-1 with either wild-type or mutant enzyme, and therefore no conclusions wether and how the interaction is relevant to the muscle-restricted pathology of hereditary inclusion body myopathy	
5.1.3.14	synthesis	transgenic Arabidopsis thaliana plants expressing three key enzymes of the mammalian Neu5Ac biosynthesis pathway: UDPN-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, N-acetylneuraminic acid phosphate synthase, and CMP-Nacetylneuraminic acid synthetase. Simultaneous expression of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase and N-acetylneuraminic acid phosphate synthase results in the generation of significant Neu5Ac amounts of 1275 nmol per g fresh weight in leaves, which can be further converted to cytidine monophospho-N-acetylneuraminic acid by coexpression of CMP-N-acetylneuraminic acid synthetase